

FDA Includes DDX3 on Pediatric Molecular Target List – Natsar’s Lead Compound RK-33 Inhibits DDX3 Leading to Cancer Cell Death

Oct. 16, 2018 – FDA’s Oncology Center of Excellence today posted a Pediatric Molecular Target List to guide submissions for pediatric study plans.

According to FDA “Recent amendments (FDARA 2017) to the Pediatric Research Equity Act (PREA) provide enhanced opportunities to extend the promise of precision medicine to children with cancer. The FDA, with input from the National Cancer Institute and the pediatric cancer research community, developed a Pediatric Molecular Target List to comply with the amended provisions of PREA to provide some guidance to industry in planning for new drug and biologic submissions.”

The list contains molecular targets which are likely to contribute to the growth or progression of at least one pediatric cancer. DDX3, an RNA helicase extensively studied by Natsar Pharmaceuticals, and the target of the Company’s lead compound RK-33, is included on the list. FDA’s inclusion of DDX3/(DDX3X) on the Pediatric Molecular Target List further validates Natsar’s groundbreaking research on this important target.

Pediatric Molecular Target List

For additional information please follow the link below.

<https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm544641.htm>

About Natsar Pharmaceuticals Inc.

Natsar is a pharmaceutical company located in Ellicott City, MD with research focused on helicases which are dysregulated in many cancer types. Lead compound RK-33, targets DDX3 and is in late stage pre-clinical studies with a phase 1 clinical trial planned for 2019. Natsar’s innovative therapies have the potential to deliver profound impact in fighting both pediatric and adult cancers including lung, brain & breast cancer, sarcoma, and many other diseases.